JP2018525367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525367A5 JP2018525367A5 JP2018504105A JP2018504105A JP2018525367A5 JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5 JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198384P | 2015-07-29 | 2015-07-29 | |
| US62/198,384 | 2015-07-29 | ||
| US201662352637P | 2016-06-21 | 2016-06-21 | |
| US62/352,637 | 2016-06-21 | ||
| PCT/IB2016/054487 WO2017017623A1 (en) | 2015-07-29 | 2016-07-27 | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525367A JP2018525367A (ja) | 2018-09-06 |
| JP2018525367A5 true JP2018525367A5 (enExample) | 2019-09-05 |
| JP6840127B2 JP6840127B2 (ja) | 2021-03-10 |
Family
ID=56682136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504105A Expired - Fee Related JP6840127B2 (ja) | 2015-07-29 | 2016-07-27 | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11001628B2 (enExample) |
| EP (1) | EP3328425B1 (enExample) |
| JP (1) | JP6840127B2 (enExample) |
| KR (1) | KR20180034426A (enExample) |
| CN (1) | CN108136003A (enExample) |
| AU (1) | AU2016300208B2 (enExample) |
| BR (1) | BR112018000212A2 (enExample) |
| CA (1) | CA2991857A1 (enExample) |
| CL (1) | CL2018000222A1 (enExample) |
| IL (1) | IL256691A (enExample) |
| JO (1) | JO3784B1 (enExample) |
| MX (1) | MX2018001263A (enExample) |
| PH (1) | PH12018500174A1 (enExample) |
| RU (1) | RU2742494C2 (enExample) |
| SA (1) | SA518390834B1 (enExample) |
| TN (1) | TN2017000554A1 (enExample) |
| TW (1) | TWI735456B (enExample) |
| WO (1) | WO2017017623A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| CA3132021C (en) | 2015-11-18 | 2024-03-12 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3106041A1 (en) | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| JP2021531751A (ja) | 2018-07-12 | 2021-11-25 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシン経路活性化を有する癌を検出および治療するための方法 |
| WO2020044252A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| CA3129031A1 (en) * | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| CN114173818A (zh) * | 2019-06-13 | 2022-03-11 | 西托姆克斯治疗公司 | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途 |
| US20220306745A1 (en) * | 2019-06-13 | 2022-09-29 | Cytomx Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| AU2005205533B2 (en) * | 2004-01-07 | 2012-03-22 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specific monoclonal antibody and uses thereof |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| WO2008023378A1 (en) * | 2006-08-23 | 2008-02-28 | Yeda Research And Development Co. Ltd | Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
| US20090270419A1 (en) * | 2006-09-15 | 2009-10-29 | Janine Arts | Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| US9827309B2 (en) * | 2013-08-20 | 2017-11-28 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| AU2014323523B2 (en) * | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| CA2935423C (en) * | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
-
2016
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja not_active Expired - Fee Related
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Ceased
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en not_active Ceased
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 US US15/879,064 patent/US11001628B2/en not_active Expired - Fee Related
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
-
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018106876A (ru) | Новая комбинация для применения при лечении злокачественного новообразования | |
| IL288012B1 (en) | Antibody molecules against lag–3 and their use | |
| MX2024004327A (es) | Moleculas pequeñas para el tratamiento del cancer. | |
| JP2019508013A5 (enExample) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2018507220A5 (enExample) | ||
| JP2016531150A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20191034T1 (hr) | Pripravci koji sadrže anti-cd38 protutijela i lenalidomid | |
| JP2019503661A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2011046732A5 (enExample) | ||
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017534645A5 (enExample) | ||
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| JP2018505882A5 (enExample) | ||
| MX2019007404A (es) | Moleculas de union a adam9 y metodos de uso de las mismas. | |
| JP2018529661A5 (enExample) | ||
| JP2018535961A5 (enExample) |